SynthesisSurgical endoscopy2025
Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.
Synthesis in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A single-center retrospective review of food retention during upper endoscopy following GLP-1 receptor agonist usage and introduction of the Tampa Intraluminal Gastric Residue (TiGR) grading scale.Surgical endoscopy · 2026Article
- Impact of glucagon-like peptide-1 receptor agonists on colonoscopy outcomes: a systematic review and meta-analysis.Clinical endoscopy · 2026Article
- GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.British journal of clinical pharmacology · 2026Observational
- GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus.Journal of clinical medicine · 2025Review
- Glucagon-like Peptide-1 Receptor Agonists and Upper Gastrointestinal Endoscopy: A Narrative Review of Residual Gastric Contents Aspiration Risk and Periprocedural Management.Euroasian journal of hepato-gastroenterologyReview
- Effect of GLP-1 receptor agonists on upper gastrointestinal endoscopy outcomes: a systematic review and meta-analysis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat diabetes and obesity. Emerging evidence suggests that GLP-1 RAs may be linked to increased gastric residual content (GRC), aspiration pneumonia, and aborted esophagogastroduodenoscopy (EGD) procedures. Although a recent meta-analysis showed an increased risk of GRC and aborted EGDs with GLP-1 RA use, it could not definitively establish a link to aspiration events due to limited data. This systematic review and meta-analysis aims to update the evidence on the impact of GLP-1 RAs on EGD outcomes, evaluate the effect of concurrent colonoscopy (CLN) on GRC, and assess the influence of different GLP-1 RA agents on GRC.
methodsWe conducted a systematic review of studies from PubMed, Embase, and Cochrane databases (until November 2024), as well as relevant abstracts from Digestive Disease Week (DDW) 2024 and American College of Gastroenterology (ACG) 2024 to assess the impact of GLP-1 receptor agonists (GLP-1 RAs) on EGD. The primary outcomes were the rate of GRC and the rate of aspiration pneumonia. Secondary outcomes included the incidence of aborted EGDs due to GRC, the effect of concurrent CLN on GRC, and a comparison of GRC risk among different GLP-1 RA agents. A network meta-analysis was conducted to assess differences in GRC risk across the various GLP-1 RAs. Results were expressed in odds ratios (ORs) and 95% confidence intervals (CI). Moreover, to account for possible confounders, adjusted ORs (mainly based on age, sex, body mass index [BMI], diabetes) were pooled and analyzed. Meta-analysis was conducted using a random-effects model in Stata 17.
resultsThe primary analysis assessing the association between GLP-1 RA use and GRC or aspiration events included 20 retrospective studies with a total of 207,708 patients (23,366 GLP-1 RA users). GLP-1 RA use demonstrated significantly higher rates of GRC compared to non-users (OR: 5.57; 95% CI: 4.07-7.62), an association that remained statistically significant on the analysis of adjusted ORs (3.18; 95% CI: 2.75-3.67). Furthermore, rates of aborted EGDs were higher with GLP-1 RA use (OR 4.90; 95% CI: 2.94-8.18), while there was no difference in aspiration events between the two groups (OR 1.75; 95% CI: 0.64-4.77). Concurrent colonoscopy was found to reduce GRC risk among GLP-1 RA users (OR 0.27; 95% CI: 0.19-0.38). A network meta-analysis comparing semaglutide (PO/SQ), exenatide, liraglutide and dulaglutide in terms of GRC showed no significant difference across these agents (chi square 0.966, p = 0.96).
conclusionThis updated systematic review and meta-analysis found a significant association between GLP-1 RA use and increased GRC. While GLP-1 RA use was linked to higher rates of aborted procedures, no difference in aspiration events was observed between the two groups. Notably, our study identified a protective effect of concurrent colonoscopy on GRC among GLP-1 RA users, while no significant differences were found in GRC risk among different GLP-1 RA agents. Further prospective studies are needed to control for potential confounders and better assess the true impact of GLP-1 RA use on EGD outcomes.
Indexed as
Identifiers
40634731What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.